Compare Meta Platforms Inc (META) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Viatris Inc — how do they compare? Meta Platforms Inc trades at $647.7 (market cap $1.64T), while Viatris Inc trades at $17 (market cap $20.14B). The key difference: Meta Platforms Inc is far larger — about 81.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| META | VTRS | |
|---|---|---|
Market Cap | $1.64T | $20.14B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $17.39 |
52-Week Low | $525.72 | $8.74 |
Enterprise Value | $1.65T | $32.35B |
Dividend Yield | 0.33% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META stock trades at $646.01, down 2.79% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $10.44 surpassing expectations of $6.70. Revenue grew to $201.0B in 2025, though net income dipped to $60.5B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $807.17. Recent news highlights the launch of Muse Spark AI and a legal ruling in Massachusetts regarding youth addiction claims.
The outlook for META is favorable, driven by AI innovation and robust financials, but risks include regulatory lawsuits and high capital expenditures. With 79% of analysts rating it a buy and a price target implying 25% upside, the stock presents a growth opportunity, though investors should weigh legal and competitive pressures against its strong market position and profitability.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
